Charles River Laboratories International, Inc. (NYSE:CRL) Director C Richard Reese sold 10,227 shares of Charles River Laboratories International stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $102.40, for a total value of $1,047,244.80. Following the completion of the transaction, the director now directly owns 51,444 shares of the company’s stock, valued at $5,267,865.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) opened at $103.84 on Friday. The firm has a market capitalization of $4,918.07, a PE ratio of 20.40, a price-to-earnings-growth ratio of 1.66 and a beta of 0.89. Charles River Laboratories International, Inc. has a twelve month low of $73.13 and a twelve month high of $119.05. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.08. The firm had revenue of $464.23 million during the quarter, compared to analysts’ expectations of $458.93 million. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The company’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.18 EPS. equities analysts anticipate that Charles River Laboratories International, Inc. will post 5.13 earnings per share for the current fiscal year.

A number of research firms recently issued reports on CRL. BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 22nd. SunTrust Banks reaffirmed a “buy” rating and issued a $113.00 price target on shares of Charles River Laboratories International in a report on Friday, November 17th. Jefferies Group reaffirmed a “buy” rating and issued a $120.00 price target on shares of Charles River Laboratories International in a report on Tuesday, September 12th. Robert W. Baird set a $117.00 price target on Charles River Laboratories International and gave the company a “buy” rating in a report on Monday, November 13th. Finally, Zacks Investment Research cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Monday, November 13th. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $106.63.

Institutional investors have recently bought and sold shares of the company. YorkBridge Wealth Partners LLC grew its position in shares of Charles River Laboratories International by 445.5% during the 3rd quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock worth $118,000 after buying an additional 891 shares during the period. Ladenburg Thalmann Financial Services Inc. grew its position in shares of Charles River Laboratories International by 69.0% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock worth $145,000 after buying an additional 548 shares during the period. Advisor Group Inc. grew its position in shares of Charles River Laboratories International by 159.4% during the 3rd quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock worth $165,000 after buying an additional 945 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Charles River Laboratories International by 12.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after buying an additional 202 shares during the period. Finally, Riverhead Capital Management LLC grew its position in shares of Charles River Laboratories International by 14.7% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after buying an additional 247 shares during the period. Institutional investors own 96.27% of the company’s stock.

TRADEMARK VIOLATION WARNING: “C Richard Reese Sells 10,227 Shares of Charles River Laboratories International, Inc. (CRL) Stock” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/12/10/c-richard-reese-sells-10227-shares-of-charles-river-laboratories-international-inc-crl-stock.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.